Prot #CA209-915: A Phase 3, Randomized Study of Adjuvant Immunotherapy with Nivolumab Combined with Ipilimumab Versus Ipilimumab or Nivolumab Monotherapy after Complete Resection of Stage IIIb/c/d or Stage IV Melanoma

Project: Research project

Project Details

StatusFinished
Effective start/end date9/7/17 → 9/7/23

Funding

  • Bristol-Myers Squibb Company ((OE) Prot #CA209-915)